Loading clinical trials...

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder

NCT00608075•University of Cincinnati

Summary

The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving lithium, an FDA-approved treatment for bipolar mania, in order to better understand who benefits from treatment and why they respond to medications. Studying this may help improve treatment and outcome in patients with bipolar disorder.

Eligibility

Age

15 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. The patient meets DSM-IV criteria for type I bipolar disorder, manic or mixed, or depressed.
•2. The patient has an index Young Mania Rating Scale (YMRS)total score \>15 or Montgomery Asberg Rating Scale (MADRS) total score \>20.
•3. The patient is between 15 and 55 years old.
•1. Healthy subjects will be between the ages of 15 and 55 years.
•2. Healthy subjects will have no history of any Axis I psychiatric disorder.
•3. Healthy subjects will have no first-degree relatives with affective or psychotic disorders.

Exclusion Criteria

•1. Any medical or neurological disorder that could influence fMRI and MRS results.
•2. A history of mental retardation or an estimated IQ total score \<85.
•3. An MRI scan is contraindicated in the subject for any reason, including psychological impediments to being inside the MR scanner.
•4. The patient cannot attend follow-up visits.

Locations (1)

University of Cincinnati

Cincinnati, Ohio, United States

Key Dates

Start Date

April 1, 2007

Primary Completion Date

July 1, 2015

Completion Date

July 1, 2017

Last Updated

October 6, 2016

Enrollment

260

ESTIMATED participants

Conditions

Bipolar I Disorder

Interventions

lithium

DRUG

Lithium

DRUG

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064

SchizophreniaBipolar I Disorder

View study

RECRUITINGPHASE3

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516

Bipolar DisorderBipolar Depression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder

Inclusion Criteria

Exclusion Criteria

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

ERG Components in Schizophrenia and Bipolar Disorder Type I

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)